Mirtazapine
- Generic Name
- Mirtazapine
- Brand Names
- Remeron
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3
- CAS Number
- 85650-52-8
- Unique Ingredient Identifier
- A051Q2099Q
- Background
Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. The effects of this drug may be observed as early as 1 week after beginning therapy.
In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.
- Indication
This drug is indicated for the treatment of major depressive disorder and its associated symptoms.
Mirtazapine has been used off-label for a variety of conditions including panic disorder, generalized anxiety disorder, dysthymia, tension headaches, hot flushes, post-traumatic stress disorder (PTSD), sleep disorders, substance abuse disorders, and sexual disorders, among others.
- Associated Conditions
- Cancer Pain, Depression, Fibromyalgia, Generalized Anxiety Disorder, Hot Flashes, Insomnia, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Persistent Depressive Disorder (Dysthymia), Post Operative Nausea and Vomiting (PONV), Poststroke depression, Sleep disorders and disturbances, Substance Abuse Disorders, Tension Headache
Pharmacovigilance in Gerontopsychiatric Patients
- Conditions
- DementiaDepressionSchizophreniaPsychosomatic DisordersAnxiety Disorders
- Interventions
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 407
- Registration Number
- NCT02374567
- Locations
- 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪Hannover Medical School, Hannover, Germany
Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 212
- Registration Number
- NCT02336750
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: Placebo (Matched to Esketamine)Drug: Placebo (Matched to Mirtazapine)
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02228239
The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled Trial
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 164
- Registration Number
- NCT02191124
- Locations
- 🇨🇳
Beijing Anding Hospital, Beijing, Beijing, China
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
- Conditions
- Major Depressive DisorderAlcohol Use Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 16
- Registration Number
- NCT02185131
- Locations
- 🇺🇸
Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States
Clinical Studies on the Therapeutic Effects of Mirtazapine on Drug-craving in Cocaine Addicts.
- Conditions
- Drug-withdrawal.Drug AbuseDrug-induced Depressive StateAOD CravingAODR Depressive State
- Interventions
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2013-09-24
- Lead Sponsor
- Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
- Target Recruit Count
- 64
- Registration Number
- NCT01949571
- Locations
- 🇲🇽
National Institute of Psychiatry, México. Distrito Federal, Distrito Federal, Mexico
Interpersonal Psychotherapy for Treatment Resistant Depression
- Conditions
- Treatment Resistant Depression
- Interventions
- Other: IPT+ antidepressant drugs
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 74
- Registration Number
- NCT01896349
- Locations
- 🇧🇷
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Phillip Coffin, MD, MIA
- Target Recruit Count
- 120
- Registration Number
- NCT01888835
- Locations
- 🇺🇸
Substance Use Research Unit, San Francisco, California, United States
Mirtazapine for Sleep Disorders in Alzheimer's Disease
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Brasilia University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT01867775
- Locations
- 🇧🇷
Brasilia University, Brasilia, Distrito Federal, Brazil
Algorithm Guided Treatment Strategies for Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Other: modified electroconvulsive therapyOther: repetitive transcranial magnetic stimulation
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 1080
- Registration Number
- NCT01764867
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.